Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Misdiagnosis of Late-Onset Pompe Disease: A Case Series
Neuromuscular and Clinical Neurophysiology (EMG)
P6 - Poster Session 6 (5:30 PM-6:30 PM)
10-009
Pompe disease is an autosomal recessive glycogen storage disease caused by deficiency of acid alpha-glucosidase (GAA), which leads to the accumulation of lysosomal glycogen. Clinically, it is primarily characterized by weakness of the cardiac, respiratory, and skeletal muscles. Late-onset Pompe disease can present later in life and is thus underrecognized and frequently misdiagnosed, leading to delayed initiation of appropriate enzyme replacement therapy and subsequent increased morbidity and mortality for patients.
To describe the initial diagnosis, time from symptom onset to initiation of treatment, and current functional status of ten patients with late-onset Pompe disease who had originally received an incorrect diagnosis.
Case series describing ten patients who initially received an incorrect diagnosis but were ultimately diagnosed with late-onset Pompe Disease.
Five patients were initially diagnosed with limb-girdle muscular dystrophy, one with unspecified muscular dystrophy, two with inflammatory myositis, one with fatty liver disease, and one did not yet have a diagnosis but had already undergone two separate liver biopsies after elevated AST/ALT had been incidentally discovered. Average time from onset of symptoms to age of diagnosis was 14.4 years. Seven of the ten patients are known to currently be on enzyme replacement therapy and remain ambulatory (with or without assistive devices). The clinical status of the other three is unknown as they have been lost to follow up.
Late-onset Pompe disease (LOPD) is underrecognized and can be misdiagnosed as a variety of other conditions including muscular dystrophy, inflammatory myositis, or even hepatic disease. These misdiagnoses lead to delays in initiation of treatment and result in morbidity and mortality for patients. There is need for education for physicians to recognize symptoms of LOPD and refer them accordingly.
Authors/Disclosures
Dennis Huang, MD (Dennis Huang)
PRESENTER
Dr. Huang has nothing to disclose.
Tahseen Mozaffar, MD, FAAN (University of California Irvine) Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Modis Therapeutics. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB/ Ra Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Maze Therapeutics. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for National Institutes of Health. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neuromuscular Disease Foundation. The institution of Dr. Mozaffar has received research support from NIH. The institution of Dr. Mozaffar has received research support from Muscular Dystrophy Association. The institution of Dr. Mozaffar has received research support from Sanofi-Genzyme. The institution of Dr. Mozaffar has received research support from Argenx. The institution of Dr. Mozaffar has received research support from Amicus Therapeutics. The institution of Dr. Mozaffar has received research support from Spark Therapeutics. The institution of Dr. Mozaffar has received research support from Audentes Therapeutics. The institution of Dr. Mozaffar has received research support from Cartesian. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH.